Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AstraZeneca Q1 2024 Adj EPADS $1.03 Misses $1.22 Estimate, Sales $12.679B Beat $11.833B Estimate

Author: Benzinga Newsdesk | April 25, 2024 02:07am
AstraZeneca (NASDAQ:AZN) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.22 by 15.57 percent. This is a 7.29 percent increase over earnings of $0.96 per share from the same period last year. The company reported quarterly sales of $12.679 billion which beat the analyst consensus estimate of $11.833 billion by 7.15 percent. This is a 16.55 percent increase over sales of $10.879 billion the same period last year.

Posted In: AZN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist